

Background

Transanal total mesorectal excision (TaTME), including transperineal abdominoperineal resection (APR), was developed to overcome the technical challenges of laparoscopic surgery for low rectal cancer.

With the increasing adoption of robotic surgery, abdominal dissection and transection around the rectum have become more feasible, and the overall indications for TaTME have declined. However, TaTME remains particularly useful in advanced rectal cancers with recurrence or adjacent organ invasion.

To ensure the safe application of transanal/transperineal (Ta/Tp) approaches in such complex cases, we have standardized the operative procedure and carefully defined indications for clinical practice.

Our indication for TaTME

Intersphincteric resection *ISR*
(Male) Abdominoperineal resection *APR*
Total pelvic indication *TPE*
Resection for local recurrence


Basic
Advanced

By establishing TaTME as a standardized procedure in routine practice, it becomes applicable to advanced cases.


Operating room setup



Procedure for TaTME



Procedure for TpAPR



Aim

To evaluate the surgical outcomes of the standardized Ta/Tp approach at our institution.

Results

TaTME was performed in 60 cases between April 2022 and May 2025.

47 patients excluding IBD were analyzed.

Patient characteristics

Sex (Male/Female)	41/6 cases
Age, median (range)	68 (32-80)
BMI, median (range) (Kg/m2)	22.6 (16.2-30.7) Kg/m2

Tumor characteristics

Primary/Recurrence	41/6 cases
Neoadjuvant therapy (None/TNT/CRT/NAC/Carbon-ion radiotherapy)	17/16/8/5/1例

Surgical results

		Time to resection	Blood loss
Primary	ISR (N=19)	166 (76-307) min	60 (0-342) ml
	APR (N=17)	184 (118-480) min	70 (0-630) ml
	TPE (N=5 including 3 cases of posterior TPE)	488 (338-564) min	200 (60-480) ml
	Recurrence (N=6)	497 (295-1073) min	350 (70-910) ml

Conclusion

Based on the standardized TaTME technique, safe application of Ta/Tp approaches is feasible even for indications extending beyond conventional TME, including advanced and recurrent rectal cancers.